Evercore ISI assumed coverage on shares of Shire PLC (NASDAQ:SHPG) in a report released on Wednesday morning, MarketBeat reports. The brokerage issued an outperform rating and a $196.00 target price on the biopharmaceutical company’s stock.
Several other analysts have also recently issued reports on the stock. Cantor Fitzgerald set a $222.00 target price on shares of Shire PLC and gave the stock a buy rating in a research note on Tuesday. Barclays PLC cut shares of Shire PLC from an overweight rating to an equal weight rating in a research note on Friday, August 11th. Jefferies Group LLC reiterated a hold rating and issued a $206.00 target price (down from $216.00) on shares of Shire PLC in a research note on Wednesday, August 9th. Zacks Investment Research upgraded shares of Shire PLC from a sell rating to a hold rating in a research note on Tuesday, August 8th. Finally, BidaskClub cut shares of Shire PLC from a sell rating to a strong sell rating in a research note on Saturday, August 5th. One research analyst has rated the stock with a sell rating, nine have given a hold rating and fifteen have assigned a buy rating to the company’s stock. Shire PLC presently has an average rating of Buy and an average price target of $220.08.
Shire PLC (NASDAQ SHPG) traded up 1.00% on Wednesday, reaching $149.93. The company’s stock had a trading volume of 585,149 shares. Shire PLC has a 12 month low of $147.28 and a 12 month high of $209.22.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, beating the Zacks’ consensus estimate of $3.53 by $0.20. The company had revenue of $3.75 billion for the quarter. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The business’s quarterly revenue was up 54.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.38 earnings per share. Equities research analysts predict that Shire PLC will post $14.92 earnings per share for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this piece of content on another website, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The correct version of this piece of content can be accessed at https://stocknewstimes.com/2017/08/17/shire-plc-shpg-now-covered-by-analysts-at-evercore-isi.html.
The company also recently announced a semiannual dividend, which will be paid on Friday, October 20th. Shareholders of record on Friday, September 8th will be issued a $0.1527 dividend. The ex-dividend date of this dividend is Thursday, September 7th. This represents a yield of 0.21%. Shire PLC’s dividend payout ratio (DPR) is presently 40.63%.
A number of hedge funds and other institutional investors have recently modified their holdings of SHPG. Dynamic Technology Lab Private Ltd purchased a new position in shares of Shire PLC during the second quarter valued at about $406,000. Verition Fund Management LLC raised its stake in shares of Shire PLC by 18.9% in the second quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock worth $490,000 after buying an additional 472 shares in the last quarter. Sterling Capital Management LLC bought a new stake in shares of Shire PLC during the second quarter worth approximately $299,000. Delphi Management Inc. MA raised its stake in shares of Shire PLC by 10.5% in the second quarter. Delphi Management Inc. MA now owns 13,350 shares of the biopharmaceutical company’s stock worth $2,206,000 after buying an additional 1,270 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its stake in shares of Shire PLC by 6.2% in the second quarter. Raymond James Financial Services Advisors Inc. now owns 6,492 shares of the biopharmaceutical company’s stock worth $1,073,000 after buying an additional 381 shares in the last quarter. 20.22% of the stock is owned by institutional investors and hedge funds.
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with MarketBeat.com's FREE daily email newsletter.
